Literature DB >> 20034108

NMR characterization of an engineered domain fusion between maltose binding protein and TEM1 beta-lactamase provides insight into its structure and allosteric mechanism.

Chapman M Wright1, Ananya Majumdar, Joel R Tolman, Marc Ostermeier.   

Abstract

RG13 is a 72 kDa engineered allosteric enzyme comprised of a fusion between maltose binding protein (MBP) and TEM1 beta-lactamase (BLA) for which maltose is a positive effector of BLA activity. We have used NMR spectroscopy to acquire [(15)N, (1)H]-TROSY-HSQC spectra of RG13 in the presence and absence of maltose. The RG13 chemical shift data was compared to the published chemical shift data of MBP and BLA. The spectra are consistent with the expectation that the individual domain structures of RG13 are substantially conserved from MBP and BLA. Differences in the spectra are consistent with the fusion geometry of MBP and BLA and the maltose-dependent differences in the kinetics of RG13 enzyme activity. In particular, the spectra provide evidence for a maltose-dependent conformational change of a key active site glutamate involved in deacylation of the enzyme-substrate intermediate. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20034108     DOI: 10.1002/prot.22657

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  12 in total

Review 1.  Converting a protein into a switch for biosensing and functional regulation.

Authors:  Margaret M Stratton; Stewart N Loh
Journal:  Protein Sci       Date:  2011-01       Impact factor: 6.725

2.  A protein therapeutic modality founded on molecular regulation.

Authors:  Chapman M Wright; R Clay Wright; James R Eshleman; Marc Ostermeier
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

3.  Engineering allosteric control to an unregulated enzyme by transfer of a regulatory domain.

Authors:  Penelope J Cross; Timothy M Allison; Renwick C J Dobson; Geoffrey B Jameson; Emily J Parker
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-23       Impact factor: 11.205

4.  The interplay between effector binding and allostery in an engineered protein switch.

Authors:  Jay H Choi; Tina Xiong; Marc Ostermeier
Journal:  Protein Sci       Date:  2016-06-24       Impact factor: 6.725

Review 5.  Protein conformational switches: from nature to design.

Authors:  Jeung-Hoi Ha; Stewart N Loh
Journal:  Chemistry       Date:  2012-06-11       Impact factor: 5.236

6.  Protein switch engineering by domain insertion.

Authors:  Manu Kanwar; R Clay Wright; Amol Date; Jennifer Tullman; Marc Ostermeier
Journal:  Methods Enzymol       Date:  2013       Impact factor: 1.600

7.  Non-allosteric enzyme switches possess larger effector-induced changes in thermodynamic stability than their non-switch analogs.

Authors:  Jay H Choi; Angela San; Marc Ostermeier
Journal:  Protein Sci       Date:  2013-03-08       Impact factor: 6.725

8.  Modular protein switches derived from antibody mimetic proteins.

Authors:  N Nicholes; A Date; P Beaujean; P Hauk; M Kanwar; M Ostermeier
Journal:  Protein Eng Des Sel       Date:  2015-12-05       Impact factor: 1.650

9.  Electrochemical activation of engineered protein switches.

Authors:  Jay H Choi; Maya Zayats; Peter C Searson; Marc Ostermeier
Journal:  Biotechnol Bioeng       Date:  2015-09-04       Impact factor: 4.530

10.  Structure of an engineered β-lactamase maltose binding protein fusion protein: insights into heterotropic allosteric regulation.

Authors:  Wei Ke; Abigail H Laurent; Morgan D Armstrong; Yuchao Chen; William E Smith; Jing Liang; Chapman M Wright; Marc Ostermeier; Focco van den Akker
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.